

#8/52
8-8-01

Docket No. 57155-D/JPW/ADM

In re application of: Christophe P.G. Gerald, et al.

Serial No.: 09/538,036

Examiner: J.F. Murphy

Filed: March 29, 2000

Group Art Unit: 1646

For: DNA ENCODING MAMMALIAN NEUROPEPTIDE FF (NPFF) RECEPTORS AND USES THEREOF

HONORABLE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

July 30, 2001

RECEIVED

S I R:

Transmitted herewith is an amendment to the above-identified application.

AUG 07 2001

TECH CENTER 1600/2900

Small entity status of this application under 37 C.P.R. § 1.9 and § 1.27 has been established by a verified statement previously submitted.

a verified statement to establish small entity status under 37 C.F.R. § 1.9 and § 1.27 is enclosed.

No additional fee is required.

The filing fee is calculated as follows:

	NUMBER AFTER AMEND- MENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	NUMBER OF EXTRA CLAIMS PRESENTED	RATE		FEE	
				SMALL ENTITY	OTHER ENTITY	SMALL ENTITY	OTHER ENTITY
Total Claims	23	- * 20	= *** 3	x \$ 9	\$ 18	= \$	\$ 54
Independent Claims	1	- ** 5	= *** 0	x \$ 40	\$ 80	= \$	\$ 0
Multiple Dependent Claims(s) Presented <u>Yes</u> <u>X</u> No				\$ 135	\$ 270	\$	\$ 0
				TOTAL ADDITIONAL FEE \$ 54.00			

08/08/2001 DTHOMAS 00000003 033125 09538036

* If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 01 FC:115 110.00, write "20" in this space.

** If the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than 3, write "3" in this space.

*** If the difference between the "NUMBER AFTER AMENDMENT" and the "HIGHEST NUMBER PREVIOUSLY PAID FOR" is less than "0", write "0" in the space.

Christophe P.G. Gerald, et al.
Serial No.: 09/538,036
Filed: March 29, 2000

RECEIVED

AUG 07 2001

Amendment Transmittal Letter
Page 2

TECH CENTER 1600/2900

The "HIGHEST NUMBER PREVIOUSLY PAID FOR" (Total or Independent) is the highest of the "NUMBER AFTER AMENDMENT" in any prior amendment or the number of claims as originally filed.

Please charge Deposit Account No. _____
in the amount of \$ _____. _____

A check in the amount of \$ 54.00 is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-3125. Three copies of this sheet are enclosed.

Any filing fees under 37 C.F.R. §1.16 for the presentation of extra claims.


Any patent application processing fees under 37 C.F.R. §1.17.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant(s)
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

 7/30/01
John P. White Date
Reg. No. 28,678



#8/Elect
Andy B
AUG 07 2001
30 8-8-01
TECH CENTER
Dkt. 57155-D/JEW/AMER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Christophe P.G. Gerald, et al.
Serial No. : 09/538,036 Group Art Unit: 1646
Filed : March 29, 2000 Examiner: J.F. Murphy
For : DNA ENCODING MAMMALIAN NEUROPEPTIDE FF
(NPFF) RECEPTORS AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
July 30, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

AMENDMENT IN RESPONSE TO JUNE 28, 2001 OFFICE ACTION

This Amendment is submitted in response to the Office Action issued June 28, 2001 by the U.S. Patent and Trademark Office in connection with the above-identified application. The fee for filing this Amendment is FIFTY-FOUR DOLLARS (\$54.00) and a check for this amount is enclosed. A response to the June 28, 2001 Office Action was due July 28, 2001. However, since July 28, 2001 is a Saturday, under 37 C.F.R. §1.7, a response may be filed on the next day which is not a Saturday, Sunday or a Federal Holiday, i.e., July 30, 2001. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the Claims:

Please cancel claims 1, 9, 11, 20, 21, 84-86, 91, 200, 201 and 212-214 without prejudice or disclaimer to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.